Azithromycin use is associated with an increased risk of death from cardiovascular causes among patients at high baseline risk. Whether azithromycin confers a similar risk in the unselected general population is unknown.
A zithromycin is a macrolide antibiotic agent primarily used for the treatment of lower and upper respiratory infections and some sexually transmitted infections. This commonly used agent is considered to be generally free of serious adverse effects, including cardiac toxicity. [1] [2] [3] [4] [5] A recent observational study, however, showed that use of azithromycin was associated with a risk of death from cardiovascular causes that was 2 to 3 times as high as the risk associated with no use of antibiotics and the risk associated with amoxicillin treatment. 6 Given that certain other macrolides are known to prolong the QT interval and therefore are thought to increase the risk of potentially lethal arrhythmias, 4, 7, 8 it has been suggested that the increased risk of death from cardiovascular causes may be attributable to a proarrhythmic effect of azithromycin. 6 The reported association was found in a study involving Medicaid beneficiaries in the United States, a population characterized by a high prevalence of coexisting conditions and high mortality rates. 6, 9 Consequently, it is uncertain whether an association between azithromycin use and cardiovascular death can be generalized to populations encountered in routine clinical practice, which have a relatively lower baseline risk of cardiovascular disease than the population of Medicaid beneficiaries in which the reported association was found. We investigated whether azithromycin was associated with an increased risk of death from cardiovascular causes, as compared with no use of antibiotics and with use of penicillin V, in a cohort of young to middle-aged adults in Denmark.
Me thods

STUDY DESIGN
In a prospective study involving a historical cohort of persons using azithromycin during the period from 1997 through 2010, we compared use with no use of antibiotics and with use of penicillin V (by far the most commonly used antibiotic in Scandinavia). The primary outcome was cardiovascular death, and the secondary outcome was death from other causes. Although the hypothesized proarrhythmic effect 6 would primarily suggest a risk of cardiac death, we used the outcome of cardiovascular death to facilitate the comparison of our results with those of the study that showed an increased cardiovascular risk with azithromycin; cardiac death was analyzed in a sensitivity analysis.
We used multiple strategies to minimize confounding and thereby increase the probability of isolating an effect attributable to azithromycin. First, we chose to study a population of young and middle-aged adults because both the baseline risk of death from cardiovascular causes and the indications for azithromycin are heterogeneous across age groups; whereas the risk of death from cardiovascular causes increases with age, the use of azithromycin is relatively uncommon among older persons in Denmark. Second, because a comparison of antibiotic use with nonuse may be susceptible to confounding by indication, azithromycin was also compared with penicillin V, each of which is indicated for upper and lower respiratory tract infections as well as for skin and soft-tissue infections. Azithromycin is also used for chlamydia, mycoplasma, and legionella infections. Third, to account for pretreatment risk factors for death from cardiovascular causes, propensity-score methods were used to incorporate a wide range of potential confounders in all analyses.
The study was approved by the Danish Data Protection Agency. Approval by an ethics committee is not required for registry-based research in Denmark.
DATA SOURCES
The study population was defined with the use of the Danish Civil Registration System 10 and included all persons living in Denmark who were 18 to 64 years of age between 1997 and 2010. Unique personal identifiers were used to link information on prescription-drug use, cause of death, and potential confounders. Data on use of azithromycin and use of penicillin V were obtained from the Danish National Prescription Registry, 11 and data on causes of death were obtained from the Danish Register of Causes of Death. 12 Information on potential baseline confounders and demographic characteristics, history of prescription-drug use, and medical history were obtained from the Civil Registration System, 10 the National Prescription Registry, 11 and the Danish National Patient Register, 13 respectively. Registers, outcome definitions, and potential confounding variables are described in the Supplementary Appendix, available with the full text of this article at NEJM.org.
STUDY COHORT
The cohort included all persons with episodes of use of oral azithromycin or penicillin V during the study period, and each participant could have multiple prescriptions during the study period. Also included were control episodes of no use of antibiotics (see the Supplementary Appendix). For inclusion, participants were required not to have been hospitalized or to have used any antibiotics within 30 days before the index date. If a person filled prescriptions for more than one antibiotic on the index date, all prescriptions on that date were excluded. To ensure adequate covariate assessment, participants were required to have lived in Denmark for at least 2 years and to have filled at least one prescription within 1 year before the index date.
PROPENSITY-SCORE MODELS
We estimated two separate propensity-score models, one including episodes of use of azithromycin and no use of antibiotics and the other including episodes of use of azithromycin and penicillin V. The individual propensities for starting azithromycin treatment were estimated with the use of logistic regression. As predictors, both propensityscore models included the same set of variables; a list of 61 potential confounders is provided in Table S1 in the Supplementary Appendix. After propensity-score estimation, episodes of azithromycin use and no antibiotic use were matched according to propensity score in a 1:1 ratio for the analysis of azithromycin versus no use of antibiotics. 14, 15 The cohort used in the analysis of azithromycin versus penicillin V included all episodes with the respective drugs, grouped according to propensity-score distribution categorized in quintiles. To assess the robustness of the results, azithromycin was also compared with penicillin V and with amoxicillin in sensitivity analyses that used propensity-scorematched information in a 1:1 ratio.
FOLLOW-UP AND TREATMENT CLASSIFICATION
Follow-up started on the index date and ended on the date of the first instance of one of the following: loss to follow-up (owing to emigration or disappearance), crossover to another antibiotic, hospitalization, end of study (January 1, 2011), day 35 after the start of treatment, or death due to noncardiovascular or cardiovascular causes.
The timing of treatment was classified as follows: current use (1 to 5 days, starting from the index date), recent use (6 to 10 days), and past use (11 to 35 days). This classification allowed us to assess the risk associated with use of azithromycin in time periods incorporating the standard treatment duration of 5 days and up to 30 days after the treatment had ended. An increase in risk that was restricted to periods of current use and that disappeared in periods of past use would reflect an acute toxic mechanism. Conversely, an increase in risk that was also present in periods of past use would reflect another mechanism or suggest unmeasured confounding.
STATISTICAL ANALYSIS
The statistical analyses were performed by means of Poisson regression. Poisson regression is appropriate in studies of rare discrete outcomes in which the risk is assumed to vary over time. P values were based on Wald tests. All statistical tests were two-sided, with P values of less than 0.05 considered to indicate statistical significance. We estimated the adjusted absolute difference in risk per 1 million treatment episodes with azithromycin as the sum of the adjusted rate ratio minus 1, times the crude rate among persons using penicillin V (see the Supplementary Appendix). Analyses were performed with the use of SAS software, version 9.3 (SAS Institute).
R e sult s COHORT SELECTION
From a source population of 4,732,867 persons, we identified 1,697,710 episodes of azithromycin use and 10,473,102 episodes of penicillin V use during the study period. The study inclusion criteria were met for 1,102,419 episodes of azithromycin use, 7,364,292 episodes of penicillin V use, and 7,084,184 control episodes of no antibiotic use. After propensity-score estimation and matching in a 1:1 ratio, the cohort used in the analysis of azithromycin versus no use of antibiotics included a total of 2,204,100 episodes. The cohort selection is shown in Figure 1 . For each episode of azithromycin use, up to 10 control episodes among persons who had the same sex and date of birth but who were not using azithromycin were randomly assigned as potential matches. Values for the exclusion criteria do not sum to the totals shown because some records were excluded for more than one reason. 
AZITHROMYCIN VS. NO USE OF ANTIBIOTICS
The baseline characteristics of participants with matched episodes of azithromycin use and no use of antibiotics are shown in Table 1 , and in Table S3 in the Supplementary Appendix. The rate ratios for death from cardiovascular causes associated with use of azithromycin, as compared with no use of antibiotics, are shown in Table 2 .
We found that the risk of death from cardiovascular causes was significantly increased with current use of azithromycin (rate ratio, 2.85; 95% confidence interval [CI], 1.13 to 7.24). No significantly increased risk was observed for recent or past use. With respect to the secondary outcome of noncardiovascular death, the rate ratio associated with current use of azithromycin was 1.60 (95% CI, 1.00 to 2.54). In a sensitivity analysis, the rate ratio for cardiac death associated with current use of azithromycin versus no antibiotic use was 3.27 (95% CI, 1.07 to 10.04). Table 1 and Table S3 in the Supplementary Appendix also show baseline characteristics for persons using azithromycin or penicillin V. As compared with persons who used penicillin V, those who used azithromycin were less likely to be men, were on average somewhat younger, were more likely to live in the greater Copenhagen area, were more likely to be taking drugs for asthma and chronic obstructive pulmonary disease, had used a larger number of prescription drugs in the previous year, and were less likely to have had an emergency department visit in the previous month. The rate ratios for the risk of death from cardiovascular causes associated with use of azithromycin, as compared with penicillin V, are shown in Table 2 . In an unadjusted analysis, current use of azithromycin, as compared with penicillin V, was not significantly associated with an increased risk of death from cardiovascular causes (rate ratio, 0.78; 95% CI, 0.47 to 1.28). Similarly, there was no significantly increased risk associated with recent or past use.
AZITHROMYCIN VS. PENICILLIN V
After adjustment for propensity scores, the results were similar; current use of azithromycin was not associated with a significantly increased risk of death from cardiovascular causes (rate ratio, 0.93; 95% CI, 0.56 to 1.55), and neither was recent use (rate ratio, 0.75; 95% CI, 0.34 to 1.62) or past use (rate ratio, 0.92; 95% CI, 0.60 to 1.42). The adjusted absolute risk difference for current azithromycin use, as compared with penicillin V use, was −1 cardiovascular death (95% CI, −9 to 11) per 1 million treatment episodes. There were 46 deaths due to noncardiovascular causes during current use of azithromycin (incidence rate, 3.1 per 1000 person-years) and 410 during current use of penicillin V (incidence rate, 4.1 per 1000 person-years), for an unadjusted rate ratio of 0.75 (95% CI, 0.55 to 1.01) and an adjusted rate ratio of 0.82 (95% CI, 0.61 to 1.12). Table 3 presents the risk of cardiovascular death in subgroups according to sex, age, and status with respect to a history of cardiovascular disease. Although the small number of events in these subgroups should be taken into account, the risk of death from cardiovascular causes during current use of azithromycin, as compared with penicillin V, did not differ significantly according to sex or according to age. The risk during current use of azithromycin appeared to be higher among persons with a history of cardiovascular disease than among those without such a history, although the difference was not significant.
SUBGROUP ANALYSES
SENSITIVITY ANALYSES
In a sensitivity analysis, the use of azithromycin, as compared with penicillin V, was not associated with an increased risk of cardiac death (adjusted rate ratio, 1.06; 95% CI, 0.60 to 1.90). The risk of death from cardiovascular causes was also analyzed after propensity-score matching (in a 1:1 ratio) of episodes of azithromycin use and penicillin V use (see Table S4 in the Supplementary Appendix); current use of azithromycin was not associated with an increased risk (rate ratio, 1.06; 95% CI, 0.54 to 2.10) ( Table 4 ). In a post hoc analysis, azithromycin use was compared with amoxicillin use in a propensity-score-matched analysis with a ratio of 1:1; azithromycin use was not associated with a significantly increased risk of death from cardiovascular causes (rate ratio, 0.60; 95% CI, 0.29 to 1.23) (Tables S5 and S6 in the Supplementary Appendix) .
Discussion
In this nationwide cohort study, we evaluated the association between use of azithromycin and death from cardiovascular causes, as compared with no use of antibiotics and with use of penicillin V, in young and middle-aged adults. As compared with no use of antibiotics, use of azithromycin was associated with a significantly increased risk of cardiovascular death. As compared with penicillin V, however, azithromycin was not associated with a significantly increased risk, indicating that the increased risk that was observed in the comparison with no antibiotic use was entirely attributable to the risk of death associated with acute infection (or some other adverse health characteristic in persons receiving antibiotic treatment, as compared with those not treated with antibiotics) rather than with its treatment.
The study included more than 1 million episodes of azithromycin use and, given the upper limit of the confidence interval, was powered to rule out a moderate-to-high increase (>55%) in the relative risk of death from cardiovascular causes. * The rate ratio was adjusted for the propensity score. † The P value for the primary analysis refers to the risk estimate for current azithromycin use versus current penicillin V use, whereas the P values for the subgroup analyses refer to the homogeneity of the risk estimate between the respective subgroup levels. ‡ Included in this category were an acute coronary syndrome, other ischemic heart disease, heart failure or cardiomyopathy, valve disorder, congenital heart disease, cardiac surgery or other invasive cardiac procedure, cerebrovascular disease, arterial disease, and arrhythmia. In terms of absolute risk, any residual risk would account for a maximum of 11 additional deaths from cardiovascular causes per 1 million treatment episodes. We did not find an increased risk of cardiovascular death associated with azithromycin, whereas Ray et al. reported a significantly increased risk that was 2 to 3 times as high as the risk associated with no antibiotic use and with amoxicillin treatment. 6 Given the profound differences in the characteristics of the study participants and the baseline risk of death between the two studies, our results provide a clinically relevant complement to, rather than a contrast with, the findings of Ray et al. Whereas their study, which examined the risk of death from cardiovascular causes associated with azithromycin in a population of U.S. Medicaid beneficiaries, provides evidence to support the hypothesis that azithromycin has an effect on cardiovascular mortality in a selected population, 6 our study shows that this effect is not present in the general population.
The mortality rates in that study were markedly higher, indicating that the study population had a higher baseline risk, as compared with the population in our study. For example, the cardiovascular mortality rate in the study by Ray et al. 6 was 85.2 deaths per 1 million courses of azithromycin, as compared with 15.4 deaths per 1 million courses in our study. The difference in the results of the two studies could thus probably be attributed to treatment-effect heterogeneitythat is, an increased risk that was largely restricted to high-risk patients. Our results also point toward an increased risk among patients with a history of cardiovascular disease, although no significant difference was observed in a comparison with patients who did not have such a history.
This study has a number of strengths. Given the large, nationally representative study population, the results are likely to be widely generalizable to young and middle-aged adult populations. We used multiple strategies to minimize confounding. The risk associated with azithromycin use was analyzed relative to two separate references: no use of antibiotics and use of penicillin V. By means of the application of propensityscore methods, we were able to take into account a wide range of pretreatment risk factors for cardiovascular death. Finally, the analysis in which penicillin V was used as the reference allowed us to compare azithromycin with a drug that has similar indications, reducing the potential for confounding by indication and unmeasured confounding. 16, 17 The study also has limitations. We did not have information on the indication for treatment for individual patients or information on several known risk factors for cardiovascular disease and death (e.g., smoking and body-mass index). Thus, residual confounding cannot be ruled out. On the assumption that propensity-score matching may provide more robust control regarding confounders than adjustment does, persons who used azithromycin were matched to those who used penicillin V in a sensitivity analysis; the results were similar to, albeit less precise than, those of the primary analysis. Furthermore, the fact that there was no significant difference between azithromycin and penicillin V among persons with past use indicates that a differential baseline risk of cardiovascular death between users of the study drugs is unlikely to have obscured a true risk associated with current use of azithromycin. The risk of cardiovascular death among persons with past use, as compared with current use, is less influenced by (or is not influenced by) the acute effects of the infection for which the treatment was previously used and is more likely to represent the baseline risk of this outcome.
In addition, the number of events in the subgroup analyses was low. The primary outcome definition, including all cardiovascular causes of death, was broad and may not have been sufficiently specific to detect an increased risk that was due to a previously hypothesized proarrhythmic effect. 6 A sensitivity analysis with the outcome restricted to cardiac deaths had similar results.
This study was prompted by a reported association between azithromycin use and cardiovascular death. 6 In a large, representative population of young and middle-aged adults, we found no significantly increased risk of death from cardiovascular causes associated with azithromycin. Viewed together with previous data, 6 our findings indicate that the risk of cardiac toxic effects associated with azithromycin may not be generalizable but may rather be limited to highrisk populations. The implications of these findings for clinical decision making are reassuring; they indicate that for the general population of patients seen in office practice, azithromycin can be prescribed without concern about an increased risk of death from cardiovascular causes, whereas the benefits of therapy need to be weighed against the risk of death from cardio-vascular causes among patients with a high baseline risk of cardiovascular disease.
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